March 2, 2022 7:22am

The market remains headline driven; I’m seeing some positives even under the shade of tanks rolling

Pre-open indications: 6 SELL indications, 5 BUY Indications and 1 pimp/pump/promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Only the facts … I ask questions and note the indications of what could happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are UP +0.67% (+223 points), S&P futures are UP +0.70% (+30 points) and NASDAQ futures are UP +0.74% (+103 points)

 

Stock futures rose Wednesday morning as the geopolitical crisis between Russia and Ukraine continues,

European stocks were flat-lining as oil and gas stocks jumped 3.7% on surging oil prices,

Asia-Pacific stocks were mixed as China and Hong Kong closed down with oil pricing up +6% while Australia and South Korea closed up still feeling the heat of the ongoing Russia-Ukraine conflict.

 

Henry’omics:

Oil prices surged amid the intensifying conflict between Russia and Ukraine as sanctions have wreaked havoc on commodity markets.

Investors remained on edge as reports Wednesday indicated that Russian forces penetrated Kherson and have surrounded Mariupol, two key cities in the southern part of the country.

 

Economic Data Docket: employment data from ADP, as well as mortgage application numbers. Fed Chair Powell will testify before Congress on Wednesday to give his semiannual monetary policy update.

 

RegMed Investors’ (RMi) closing bell: “

Ebb and flow –

·         March – 1 negative close

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes

 

Research Notes:

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... added (PGEN) and (RGNX)– 19 total

The Biostage (OTC: QB: BSTG) Chronicles: Who, What, When, Where, Why and one H (HOW) … https://www.regmedinvestors.com/articles/12306

UC Berkeley loses CRISPR patent case, invalidating licenses it granted gene-editing companies https://www.regmedinvestors.com/articles/12320

 

 

Companies in my headlights – It’s your decision; I provide ideas and context:

SELL into Strength indications:

  • Alnylam Pharmaceuticals (ALNY +$4.66 after Monday’s +$2.85) with a pre-open indication $0.00 or 0.00%
  • Ionis Pharmaceuticals (IONS +$0.70 after Monday’s +$1.60) with a pre-open indication -$0.05 or -0.15%
  • CRISPR Therapeutics (CRSP -$3.93 after Monday’s +$1.64 after Friday’s +$2.57) with a pre-open indication +$0.26 or +0.45%
  • Global Blood Therapeutics (GBT -$0.33 after Monday’s +$0.36) with a pre-open indication +$0.13 or +0.44%
  • Sangamo Therapeutics (SGMO +$0.03 after Monday’s -$0.05) with a pre-open indication of -0.29 or -4.93%
  • ReNeuron (RENE.L +$1.00 after Thursday’s +$1.50) with a pre-open indication of -1.47 or -4.97% and departure of its CEO, Olav Hellebø,

 

BUY:

  • Applied Genetic Technologies (AGTC -$0.04) with a pre-open indication +$0.06 or +3.08%
  • Editas Medicine (EDIT +$0.37 after Monday’s $0.22) with a pre-open indication +$0.02 or +0.11%
  • Homology Medicine (FIXX +$0.06 after Monday’s -$0.67) with a pre-open indication +$0.14 or +3.94%
  • Intellia Therapeutics (NTLA -$19.00 after Monday’s +$2.49 after Friday’s +$8.90) with a pre-open indication +$4.50 or +5.64%
  • Pluristem (PSTI -$0.09 after Monday’s +$0.07) with a pre-open indication +$0.15 or +8.77%

 

Pimp/Pump and Promote:

Biostage (OTCQB: BSTG) closed down -$0.04 with 4,359 shares traded after Monday’s +$0.37 with 687 shares traded after Friday’s flat with 70 shares traded after Thursday’s -$0.62 with a “sudden block” of 1,259 share traded after Wednesday’s +$0.20 with an “out-of-the air” block of 3,070 after Tuesday’s +$0.62 with 4,225 shares traded – doesn’t the term – “zombie” fit this equity.

WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?

·         Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering - they’re NOT going ANYWHERE without a cash inflow.

 

The BOTTOM LINE: My select sector cell and gene therapy comparables held onto the bulk of their recent gains.

However, given the extreme volatility, sector investors may want to take some profits in some recent winners.

Earnings’ reporting on the horizon:

·         Fate Therapeutics, Monday, 2/28

·         BioLife Solutions (BLFS), Monday,2/28

·         Athersys (ATHX), Tuesday, 3/15

Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency, financial irregularities and more; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.